Vaxart Q2 FY26 net loss narrows 10% to $13.49 million; revenue falls 32% to $27.19 million

Reuters2026/08/06 21:46

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Vaxart posted Q2 net loss of USD 13.49 million, narrowing 10% year over year, as revenue fell 32% to USD 27.19 million.
Operating loss improved to USD 13.17 million, while operating expenses dropped 26% to USD 40.36 million.
Government-contract revenue slid 39% to USD 24.26 million, while collaboration revenue turned positive at USD 2.92 million.
R&D expense decreased 32% to USD 33.75 million, due to lower COVID-19 trial, personnel, facilities, preclinical and manufacturing costs.
Vaxart reported 12-month Phase 2b sentinel COVID-19 cohort data with no vaccine-related serious adverse events; full study topline data are expected in H1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxart Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-026289), on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Vaxart Q2 FY26 net loss narrows 10% to $13.49 million; revenue falls 32% to $27.19 million

You may also like

Crypto prices